Arcturus Therapeutics Holdings Inc

$12.81

(as of Apr 30, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Arcturus Therapeutics Holdings Inc

Stock Price

$12.81

Ticker Symbol

ARCT

Exchange

NASDAQ

Industry Information for Arcturus Therapeutics Holdings Inc

Sector

Healthcare

Industry

Biotechnology

Company Description for Arcturus Therapeutics Holdings Inc

Website

https://arcturusrx.com

Country

USA

Full Time Employees

174

Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Fundamentals for Arcturus Therapeutics Holdings Inc

Market Capitalization

$347,675,840

EBITDA

$-92,125,000

Dividends per Share

P/E Ratio

Forward P/E Ratio

2.48

Earnings per Share

$-3

Earnings per Share Estimate Next Year

Profit Margin

-53.14%

Shares Outstanding

27,119,800

Percent Owned by Insiders

8.45%

Percent Owned by Institutions

92.13%

52-Week High

52-Week Low

Technical Indicators for Arcturus Therapeutics Holdings Inc

50-Day Moving Average

200-Day Moving Average

RSI

59.05

ATR

0.96

Analyst Ratings for Arcturus Therapeutics Holdings Inc

Strong Buy

Buy

Hold

Sell

Strong Sell

News About Arcturus Therapeutics Holdings Inc

Feb 14, 2025, 8:30 AM EST

- KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA COVID-19 vaccines in clinical trials See more.

Jan 7, 2025, 11:26 AM EST

Tuesday saw bumps in Moderna (NASDAQ:MRNA), Novavax (NASDAQ:NVAX), and other vaccine producers as worries about rising COVID-19 and flu infections in the United States drove demand for immunization-oriented businesses to continue growing. See more.

Sep 30, 2024, 11:12 AM EST

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses See more.

Sep 30, 2024, 8:00 AM EST

Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of immune response; Results highlight CSL and Arcturus Therapeutics’ commitment to advancing COVID-19 vaccine innovation to protect public health. See more.